title: Recovery of ovarian function and pregnancy in a patient with AML after myeloablative busulphan-based conditioning regimen.
abstract: We report a rare case of ovarian function recovery and pregnancy after hormone-replacement therapy (HRT) in the acute myeloblastic leukemia (AML) patient in third complete remission received hematopoietic stem cell transplantation (HSCT) with busulphan-based conditioning regimen. Successful engraftment of the donor cells and full donor's chimerism was achieved without the signs of leukemia. One year after HSCT the patient received a course of HRT as a treatment of hypergonadotropic hypogonadism. After 12 months of HRT the recovery of ovarian function was confirmed. Eight years after the HSCT spontaneous pregnancy occurred; heartbeat of the fetus was registered on week 7. Three weeks later a nonsevere vaginal bleeding occurred and the ultrasound examination showed a nondeveloping pregnancy. Genetic examination of the abortion material showed a full triploid genotype (69 XXX). To our knowledge this is a first case of ovarian function restoration and spontaneous pregnancy in a AML patient after multiple courses of high-dose chemotherapy and busulphan-based myeloablative conditioning for HSCT.
authors.affiliation: Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia. bala8@yandex.ru
authors.forename: Dmitry N
authors.initials: DN
authors.lastname: Balashov
authors.forename: Ludmila I
authors.initials: LI
authors.lastname: Papusha
authors.forename: Tatiana A
authors.initials: TA
authors.lastname: Nazarenko
authors.forename: Pavel E
authors.initials: PE
authors.lastname: Trakhtman
authors.forename: Nino A
authors.initials: NA
authors.lastname: Revishvili
authors.forename: Alexei A
authors.initials: AA
authors.lastname: Maschan
authors.forename: Marina I
authors.initials: MI
authors.lastname: Persiantseva
authors.forename: Anna V
authors.initials: AV
authors.lastname: Andriutsa
authors.forename: Elena V
authors.initials: EV
authors.lastname: Skorobogatova
authors.forename: Yulia V
authors.initials: YV
authors.lastname: Skvortsova
authors.forename: Alexander G
authors.initials: AG
authors.lastname: Rumiantsev
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D002066:Busulfan / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D019653:Myeloablative Agonists / Q000008:administration & dosage / Q000009:adverse effects; D010053:Ovary / Q000502:physiology*; D011247:Pregnancy; D011256:Pregnancy Outcome; D020127:Recovery of Function; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D019653:Myeloablative Agonists; D002066:Busulfan